Opdivo has priority review in US for Advanced Melanoma and Breakthrough Designation and accelerated assessment at EMA- BMS + Ono Pharma

In the U.S., the FDA has accepted for priority review the Biologics License Application (BLA) for Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor from BMS for previously treated Advanced Melanoma and the Prescription Drug User Fee Act (PDUFA) goal date for a decision is March 30, 2015. The FDA also granted Opdivo Breakthrough Therapy status for this indication. In the European Union, the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for Opdivo in Advanced Melanoma. The application has also been granted accelerated assessment by the EMA�s Committee for Medicinal Products for Human Use (CHMP).